The Experts below are selected from a list of 48 Experts worldwide ranked by ideXlab platform
Hirofumi Hamada - One of the best experts on this subject based on the ideXlab platform.
-
in vivo antitumor effect of cytotoxic t lymphocytes engineered to produce interferon gamma by adenovirus mediated Genetic Transduction
Biochemical and Biophysical Research Communications, 1996Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Rikiya Tsunoda, Satoshi Okabe, Hirofumi HamadaAbstract:Immunotherapy with adoptive transfer of Genetically-modified cytotoxic T lymphocytes (CTL) is a promising approach for cancer gene therapy. We developed an adoptive therapy model with murine tumor-specific CTL, to which very efficient (up to 100%) gene introduction was achieved by using recombinant adenoviral vectors. Through a comparative study on the antitumor effects of CTL Genetically modified with cytokine genes, Transduction with interferon-gamma gene resulted in a prominent increase in therapeutic efficacy of CTL in both metastatic and subcutaneous tumor models. Further additive effect was obtained by the adoptive cellular therapy in combination with vaccination of cytokine gene-modified tumor cells. Our findings provide a hopeful strategy of adoptive immunotherapy for human cancers.
-
antitumor effect induced by granulocyte macrophage colony stimulating factor gene modified tumor vaccination comparison of adenovirus and retrovirus mediated Genetic Transduction
Journal of Cancer Research and Clinical Oncology, 1995Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Hirofumi HamadaAbstract:Irradiated tumor cells Genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine) are potent stimulators of systemic antitumor immunity. For the preparation of a GM-CSF gene-modified tumor vaccine, it is important to achieve efficient Genetic Transduction of tumor cells, leading to an appropriate expression of the induced gene. In this report, with a view to developing a protocol for an effective cancer vaccination therapy, we examined the vaccination efficacies of tumor cells secreting GM-CSF by either adenovirus-or retrovirus-mediated Genetic Transduction. By using an adenoviral vector, Adex1CAmGMCSF, a highly efficient gene were achieved. Unexpectedly, animal vaccination studies showe that the GM-CSF tumor vaccine transduced with the Adex1CAmGMCSF recombinant adenovirus (adenoviral GM-CSF tumor vaccine) was less efficacious than that transduced with the MFGmGMCSF recombinant retrovirus (retroviral GM-CSF tumor vaccine). The GM-CSF serum concentration attained by the adenoviral GM-CSF tumor vaccine was much higher than that obtained by the retroviral GM-CSF tumor vaccine. Our findings indicate that an optimal level of GM-CSF production is important for the tumor vaccine to elicit an adequate response in the host antitumor immunity.
Junko Abe - One of the best experts on this subject based on the ideXlab platform.
-
in vivo antitumor effect of cytotoxic t lymphocytes engineered to produce interferon gamma by adenovirus mediated Genetic Transduction
Biochemical and Biophysical Research Communications, 1996Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Rikiya Tsunoda, Satoshi Okabe, Hirofumi HamadaAbstract:Immunotherapy with adoptive transfer of Genetically-modified cytotoxic T lymphocytes (CTL) is a promising approach for cancer gene therapy. We developed an adoptive therapy model with murine tumor-specific CTL, to which very efficient (up to 100%) gene introduction was achieved by using recombinant adenoviral vectors. Through a comparative study on the antitumor effects of CTL Genetically modified with cytokine genes, Transduction with interferon-gamma gene resulted in a prominent increase in therapeutic efficacy of CTL in both metastatic and subcutaneous tumor models. Further additive effect was obtained by the adoptive cellular therapy in combination with vaccination of cytokine gene-modified tumor cells. Our findings provide a hopeful strategy of adoptive immunotherapy for human cancers.
-
antitumor effect induced by granulocyte macrophage colony stimulating factor gene modified tumor vaccination comparison of adenovirus and retrovirus mediated Genetic Transduction
Journal of Cancer Research and Clinical Oncology, 1995Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Hirofumi HamadaAbstract:Irradiated tumor cells Genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine) are potent stimulators of systemic antitumor immunity. For the preparation of a GM-CSF gene-modified tumor vaccine, it is important to achieve efficient Genetic Transduction of tumor cells, leading to an appropriate expression of the induced gene. In this report, with a view to developing a protocol for an effective cancer vaccination therapy, we examined the vaccination efficacies of tumor cells secreting GM-CSF by either adenovirus-or retrovirus-mediated Genetic Transduction. By using an adenoviral vector, Adex1CAmGMCSF, a highly efficient gene were achieved. Unexpectedly, animal vaccination studies showe that the GM-CSF tumor vaccine transduced with the Adex1CAmGMCSF recombinant adenovirus (adenoviral GM-CSF tumor vaccine) was less efficacious than that transduced with the MFGmGMCSF recombinant retrovirus (retroviral GM-CSF tumor vaccine). The GM-CSF serum concentration attained by the adenoviral GM-CSF tumor vaccine was much higher than that obtained by the retroviral GM-CSF tumor vaccine. Our findings indicate that an optimal level of GM-CSF production is important for the tumor vaccine to elicit an adequate response in the host antitumor immunity.
Kimiyoshi Hirakawa - One of the best experts on this subject based on the ideXlab platform.
-
in vivo antitumor effect of cytotoxic t lymphocytes engineered to produce interferon gamma by adenovirus mediated Genetic Transduction
Biochemical and Biophysical Research Communications, 1996Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Rikiya Tsunoda, Satoshi Okabe, Hirofumi HamadaAbstract:Immunotherapy with adoptive transfer of Genetically-modified cytotoxic T lymphocytes (CTL) is a promising approach for cancer gene therapy. We developed an adoptive therapy model with murine tumor-specific CTL, to which very efficient (up to 100%) gene introduction was achieved by using recombinant adenoviral vectors. Through a comparative study on the antitumor effects of CTL Genetically modified with cytokine genes, Transduction with interferon-gamma gene resulted in a prominent increase in therapeutic efficacy of CTL in both metastatic and subcutaneous tumor models. Further additive effect was obtained by the adoptive cellular therapy in combination with vaccination of cytokine gene-modified tumor cells. Our findings provide a hopeful strategy of adoptive immunotherapy for human cancers.
-
antitumor effect induced by granulocyte macrophage colony stimulating factor gene modified tumor vaccination comparison of adenovirus and retrovirus mediated Genetic Transduction
Journal of Cancer Research and Clinical Oncology, 1995Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Hirofumi HamadaAbstract:Irradiated tumor cells Genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine) are potent stimulators of systemic antitumor immunity. For the preparation of a GM-CSF gene-modified tumor vaccine, it is important to achieve efficient Genetic Transduction of tumor cells, leading to an appropriate expression of the induced gene. In this report, with a view to developing a protocol for an effective cancer vaccination therapy, we examined the vaccination efficacies of tumor cells secreting GM-CSF by either adenovirus-or retrovirus-mediated Genetic Transduction. By using an adenoviral vector, Adex1CAmGMCSF, a highly efficient gene were achieved. Unexpectedly, animal vaccination studies showe that the GM-CSF tumor vaccine transduced with the Adex1CAmGMCSF recombinant adenovirus (adenoviral GM-CSF tumor vaccine) was less efficacious than that transduced with the MFGmGMCSF recombinant retrovirus (retroviral GM-CSF tumor vaccine). The GM-CSF serum concentration attained by the adenoviral GM-CSF tumor vaccine was much higher than that obtained by the retroviral GM-CSF tumor vaccine. Our findings indicate that an optimal level of GM-CSF production is important for the tumor vaccine to elicit an adequate response in the host antitumor immunity.
Masaru Aoyagi - One of the best experts on this subject based on the ideXlab platform.
-
in vivo antitumor effect of cytotoxic t lymphocytes engineered to produce interferon gamma by adenovirus mediated Genetic Transduction
Biochemical and Biophysical Research Communications, 1996Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Rikiya Tsunoda, Satoshi Okabe, Hirofumi HamadaAbstract:Immunotherapy with adoptive transfer of Genetically-modified cytotoxic T lymphocytes (CTL) is a promising approach for cancer gene therapy. We developed an adoptive therapy model with murine tumor-specific CTL, to which very efficient (up to 100%) gene introduction was achieved by using recombinant adenoviral vectors. Through a comparative study on the antitumor effects of CTL Genetically modified with cytokine genes, Transduction with interferon-gamma gene resulted in a prominent increase in therapeutic efficacy of CTL in both metastatic and subcutaneous tumor models. Further additive effect was obtained by the adoptive cellular therapy in combination with vaccination of cytokine gene-modified tumor cells. Our findings provide a hopeful strategy of adoptive immunotherapy for human cancers.
-
antitumor effect induced by granulocyte macrophage colony stimulating factor gene modified tumor vaccination comparison of adenovirus and retrovirus mediated Genetic Transduction
Journal of Cancer Research and Clinical Oncology, 1995Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Hirofumi HamadaAbstract:Irradiated tumor cells Genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine) are potent stimulators of systemic antitumor immunity. For the preparation of a GM-CSF gene-modified tumor vaccine, it is important to achieve efficient Genetic Transduction of tumor cells, leading to an appropriate expression of the induced gene. In this report, with a view to developing a protocol for an effective cancer vaccination therapy, we examined the vaccination efficacies of tumor cells secreting GM-CSF by either adenovirus-or retrovirus-mediated Genetic Transduction. By using an adenoviral vector, Adex1CAmGMCSF, a highly efficient gene were achieved. Unexpectedly, animal vaccination studies showe that the GM-CSF tumor vaccine transduced with the Adex1CAmGMCSF recombinant adenovirus (adenoviral GM-CSF tumor vaccine) was less efficacious than that transduced with the MFGmGMCSF recombinant retrovirus (retroviral GM-CSF tumor vaccine). The GM-CSF serum concentration attained by the adenoviral GM-CSF tumor vaccine was much higher than that obtained by the retroviral GM-CSF tumor vaccine. Our findings indicate that an optimal level of GM-CSF production is important for the tumor vaccine to elicit an adequate response in the host antitumor immunity.
Yoko Yoshida - One of the best experts on this subject based on the ideXlab platform.
-
in vivo antitumor effect of cytotoxic t lymphocytes engineered to produce interferon gamma by adenovirus mediated Genetic Transduction
Biochemical and Biophysical Research Communications, 1996Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Rikiya Tsunoda, Satoshi Okabe, Hirofumi HamadaAbstract:Immunotherapy with adoptive transfer of Genetically-modified cytotoxic T lymphocytes (CTL) is a promising approach for cancer gene therapy. We developed an adoptive therapy model with murine tumor-specific CTL, to which very efficient (up to 100%) gene introduction was achieved by using recombinant adenoviral vectors. Through a comparative study on the antitumor effects of CTL Genetically modified with cytokine genes, Transduction with interferon-gamma gene resulted in a prominent increase in therapeutic efficacy of CTL in both metastatic and subcutaneous tumor models. Further additive effect was obtained by the adoptive cellular therapy in combination with vaccination of cytokine gene-modified tumor cells. Our findings provide a hopeful strategy of adoptive immunotherapy for human cancers.
-
antitumor effect induced by granulocyte macrophage colony stimulating factor gene modified tumor vaccination comparison of adenovirus and retrovirus mediated Genetic Transduction
Journal of Cancer Research and Clinical Oncology, 1995Co-Authors: Junko Abe, Hiroaki Wakimoto, Yoko Yoshida, Masaru Aoyagi, Kimiyoshi Hirakawa, Hirofumi HamadaAbstract:Irradiated tumor cells Genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine) are potent stimulators of systemic antitumor immunity. For the preparation of a GM-CSF gene-modified tumor vaccine, it is important to achieve efficient Genetic Transduction of tumor cells, leading to an appropriate expression of the induced gene. In this report, with a view to developing a protocol for an effective cancer vaccination therapy, we examined the vaccination efficacies of tumor cells secreting GM-CSF by either adenovirus-or retrovirus-mediated Genetic Transduction. By using an adenoviral vector, Adex1CAmGMCSF, a highly efficient gene were achieved. Unexpectedly, animal vaccination studies showe that the GM-CSF tumor vaccine transduced with the Adex1CAmGMCSF recombinant adenovirus (adenoviral GM-CSF tumor vaccine) was less efficacious than that transduced with the MFGmGMCSF recombinant retrovirus (retroviral GM-CSF tumor vaccine). The GM-CSF serum concentration attained by the adenoviral GM-CSF tumor vaccine was much higher than that obtained by the retroviral GM-CSF tumor vaccine. Our findings indicate that an optimal level of GM-CSF production is important for the tumor vaccine to elicit an adequate response in the host antitumor immunity.